Enfortumab vedotin plus pembrolizumab is more effective than platinum-based chemotherapy in metastatic urothelial carcinoma

1. In the management of adult patients with metastatic urothelial carcinoma (MUC), enfortumab vedotin plus pembrolizumab (EV/P) was well-tolerated and significantly more effective than gemcitabine plus cisplatin (G/C). Evidence Rating Level: 2 (Good) Recent clinical trials have demonstrated that EV/P offers greater overall survival (OS) and progression-free survival (PFS) compared with…